I have been involved with immune therapy for treating cancer for many years and one of my particular areas of experience is in the use of viruses and bacterial peptides to trigger an immune reaction against cancer. I was the first doctor in the world to use adenovirus 36 Gendicine to treat certain cancers successfully. I continue to use RigVir oncolytic virus to treat several types of cancer. One of the types of cancer that I have had the most amazing results with treating using RigVir is bladder cancer.
The history of using viruses and bacteria to treat cancer actually dates back to the late 1800’s in Europe and North America when doctors reported spontaneous remission from terminal cases of cancer when those people developed a fever when they were infected with certain viruses or certain bacteria. Eventually some doctors identified the specific bacteria that triggered the immune response and developed an immunization made from the bacteria to treat people living with cancer. The most famous doctor to head this line of treatment was William Coley. Ironically, Dr. Coley’s immune therapy was so successful in comparison to other treatments that the hospital he worked at because a famous cancer treatment hospital when millions of dollars were donated for his research. The irony is that that hospital took the money and used it to push other less successful but much more profitable treatments and eventually stopped offering Coley’s immune therapy. Yep…That is Sloan Kettering Hospital. They and most main-stream cancer industry hospitals now are re-looking at immune therapy.
One hospital on the UK just presented impressive research results for treatment of bladder cancer with coxsackievirus A21. The research was published in”Clinical cancer Research”. I would love to dive into the science but actually it is quite simple. This new research re-confirms what I have explained to countless people facing cancer, the use of an oncolytic virus like RigVir works by two known ways.
First, RigVir directly infects cancer cells and killings them. The RigVir virus replicates in the cancer cell and then kills more cancer cells with the new RigVir particles made in the cancer cell.
Secondly, the RigVir also activates the immune system acute inflammation pathways to signal killer T cells and other immune cells to target any cancer cell tagged with the RigVir oncolytic virus.
Sure, there are several viruses and some bacteria that can trigger similar immune reactions but most of those viruses and bacteria are pathogens (meaning they can cause infections). What makes RigVir unique in this important field of immune therapy is the fact that Rigvir has been studied for over 50 years and it doesn’t cause any known infection in humans. This makes RigVir an effective and the safest treatment option for many people with cancer.